We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
Read MoreHide Full Article
Shares of Alterity Therapeutics (ATHE - Free Report) skyrocketed 153% on Monday after management announced promising new data from a preclinical study evaluating its lead candidate ATH434 in monkeys with experimentally-induced Parkinson's disease (PD).
The preclinical study compared daily oral doses of ATH434 with placebo over 12-14 weeks in monkeys after Parkinsonian symptoms were evident. Data from the study showed that treatment with ATH434 improved motor performance and general function, as measured by the Parkinson Behavior Rating Scale (PBRS).
Per Alterity, the favorable impact on PD symptoms was associated with lower iron levels in the area of pathology. In addition, treatment with ATH434 also showed an increase in levels of synaptophysin, a protein marker that reflects functional connections between neurons.
An oral candidate, ATH434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
Year to date, shares of Alterity Therapeutics have risen 20.6% against the industry’s 21.1% decline.
Image Source: Zacks Investment Research
Management claims that the above preclinical data will help the company improve its ability to predict clinical outcomes from the two ongoing mid-stage studies evaluating ATH434 as a potential treatment for Multiple System Atrophy (MSA), a rare neurodegenerative disease. A Parkinsonian disorder, MSA is marked by an underlying pathology similar to PD.
These preclinical results also validate the approach management is using in the clinical studies in MSA indication.
Alterity is currently evaluating ATH434 across two separate mid-stage studies in early-stage MSA and more advanced MSA. The therapy has been granted orphan drug designation in treating MSA indications by the FDA and the European Medicines Agency.
In the past 60 days, estimates for CytomX Therapeutics’ 2023 loss per share have improved from 37 cents to 6 cents. During the same period, the loss estimates per share for 2024 have narrowed from 51 cents to 21 cents. Shares of CytomX have lost 10.0% in the year-to-date period.
CytomX Therapeutics’ earnings beat estimates in three of the last four quarters while missing the estimates on one occasion. On average, the company witnessed an average surprise of 45.44%. In the last reported quarter, CytomX Therapeutics’ earnings beat estimates by 123.53%.
In the past 60 days, estimates for Novo Nordisk’s 2023 earnings per share (EPS) have increased from $2.19 to $2.62. During the same period, the earnings estimates per share for 2024 have risen from $2.54 to $3.07. Shares of NVO have surged 49.1% in the year-to-date period.
Novo Nordisk’s earnings beat estimates in two of the last four quarters while meeting the mark on one occasion and missing the estimates on another. On average, the company witnessed an average surprise of 0.58%. In the last reported quarter, Novo Nordisk’s earnings beat estimates by 5.80%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 EPS have increased from 67 cents to 72 cents. During the same period, the earnings estimates per share for 2024 have risen from 55 cents to 64 cents. Shares of PBYI have lost 10.2% in the year-to-date period.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while meeting the mark on one occasion, witnessing an average surprise of 76.55%. In the last reported quarter, Puma Biotechnology’s earnings beat estimates by 13.33%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
Shares of Alterity Therapeutics (ATHE - Free Report) skyrocketed 153% on Monday after management announced promising new data from a preclinical study evaluating its lead candidate ATH434 in monkeys with experimentally-induced Parkinson's disease (PD).
The preclinical study compared daily oral doses of ATH434 with placebo over 12-14 weeks in monkeys after Parkinsonian symptoms were evident. Data from the study showed that treatment with ATH434 improved motor performance and general function, as measured by the Parkinson Behavior Rating Scale (PBRS).
Per Alterity, the favorable impact on PD symptoms was associated with lower iron levels in the area of pathology. In addition, treatment with ATH434 also showed an increase in levels of synaptophysin, a protein marker that reflects functional connections between neurons.
An oral candidate, ATH434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
Year to date, shares of Alterity Therapeutics have risen 20.6% against the industry’s 21.1% decline.
Image Source: Zacks Investment Research
Management claims that the above preclinical data will help the company improve its ability to predict clinical outcomes from the two ongoing mid-stage studies evaluating ATH434 as a potential treatment for Multiple System Atrophy (MSA), a rare neurodegenerative disease. A Parkinsonian disorder, MSA is marked by an underlying pathology similar to PD.
These preclinical results also validate the approach management is using in the clinical studies in MSA indication.
Alterity is currently evaluating ATH434 across two separate mid-stage studies in early-stage MSA and more advanced MSA. The therapy has been granted orphan drug designation in treating MSA indications by the FDA and the European Medicines Agency.
Zacks Rank & Key Picks
Alterity Therapeutics currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the overall healthcare sector include CytomX Therapeutics (CTMX - Free Report) , Novo Nordisk (NVO - Free Report) and Puma Biotechnology (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CytomX Therapeutics’ 2023 loss per share have improved from 37 cents to 6 cents. During the same period, the loss estimates per share for 2024 have narrowed from 51 cents to 21 cents. Shares of CytomX have lost 10.0% in the year-to-date period.
CytomX Therapeutics’ earnings beat estimates in three of the last four quarters while missing the estimates on one occasion. On average, the company witnessed an average surprise of 45.44%. In the last reported quarter, CytomX Therapeutics’ earnings beat estimates by 123.53%.
In the past 60 days, estimates for Novo Nordisk’s 2023 earnings per share (EPS) have increased from $2.19 to $2.62. During the same period, the earnings estimates per share for 2024 have risen from $2.54 to $3.07. Shares of NVO have surged 49.1% in the year-to-date period.
Novo Nordisk’s earnings beat estimates in two of the last four quarters while meeting the mark on one occasion and missing the estimates on another. On average, the company witnessed an average surprise of 0.58%. In the last reported quarter, Novo Nordisk’s earnings beat estimates by 5.80%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 EPS have increased from 67 cents to 72 cents. During the same period, the earnings estimates per share for 2024 have risen from 55 cents to 64 cents. Shares of PBYI have lost 10.2% in the year-to-date period.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while meeting the mark on one occasion, witnessing an average surprise of 76.55%. In the last reported quarter, Puma Biotechnology’s earnings beat estimates by 13.33%.